A Phase II Study of Pembrolizumab Immunotherapy, Olaparib, and Temozolomide in People with Recurrent Glioma

Full Title

Purpose

The purpose of this study is to assess the safety and effectiveness of combining three drugs to treat people with an IDH-mutant glioma that came back after chemotherapy or surgery. The three medications are pembrolizumab, olaparib, and temozolomide. 

Pembrolizumab takes the brakes off the immune response, helping immune cells to find and destroy cancer cells. Olaparib blocks a protein called PARP that repairs damage to a cell’s DNA before the cell divides and can make cancers more vulnerable to treatment. Temozolomide is the current standard of care for most gliomas; the drug prevents DNA repair in cancer cells. Pembrolizumab is given intravenously (by vein) and olaparib and temozolomide are taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Lauren Schaff’s office at 212-610-0485.